Showing Results for
From:PLoS ONE (Vol. 16, Issue 7) Peer-ReviewedDevelopment of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is...
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it